TMRP Surrogate Outcomes Interest Group meeting, Wed 5th June 2024 @1400

Our next TMRP Surrogate Outcomes Interest Group meeting will take place on Teams on Wednesday 5th June 2024 @1400-1530 UK time.

We are delighted that three members of the NICE technical team have agreed to give a joint presentation for our meeting on the role of surrogates in HTA – see details of the presentation and our outline meeting agenda below.

We much hope you will be able to join us!

Best wishes. Hannah Ensor & Rod Taylor, subgroup co-leads & Pok Lo, PhD student rep.

Surrogate outcomes in cost-effectiveness analysis for use in health technology assessment

There has been an increase in drugs that are approved based on improving a surrogate outcome in clinical trials. This means HTA agencies don’t always have evidence for longer-term effects when a new technology is submitted for assessment. NICE is working with a group of international HTA organisations who make recommendations for the use of new drugs to develop more guidance on the use of surrogate outcomes when analysing cost-effectiveness. The guidance will help pharmaceutical companies understand how surrogate outcomes should be used when analysing cost-effectiveness of the drugs they are developing. Information about the agencies working on the project can be found in a blog: How ‘surrogate outcomes’ influence long-term health outcomes (nice.org.uk)

Presenters

Laura Flight is currently a Scientific Adviser in the Science Policy and Research team at the National Institute for Health and Care Excellence (NICE), UK. Previously she worked as a Research Fellow in Health Economics and Statistics at the Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield. Laura’s methodological research to date has focussed on innovative approaches to the design and conduct of clinical trials with an emphasis on how novel statistical methods can be applied in practice.

Fatima Salih is a Scientific Adviser in the National Institute for Health and Care Excellence (NICE) Science, Policy and Research Programme. She has over 10 years’ experience in health technology assessment (HTA) of interventions for reimbursement in the NHS, in addition to public health experience in the UK and Sudan. More recently, she has been involved in projects focused on HTA considerations for surrogate outcomes and interventions for neurodegenerative disorders both from a UK and a wider European perspective.

Zoe Garrett is a Senior Scientific Adviser in the National Institute for Health and Care Excellence (NICE) Science, Policy and Research Programme. She has worked for NICE since 2005 initially in the technology appraisals programme before working on the European Network for Health Technology Assessment (EUnetHTA) JA3. More recently, Zoe has worked to support international collaboration at NICE maintaining relationships with international HTA agencies and facilitating collaborative HTA projects.

Proposed Meeting Agenda

1. Welcome & introduction to any new members.
2. Seminar from NICE & questions/answers – 40mins
3. Any updates/news items (all)
4. Any other business
5. Timing of next meeting